Fintel reports that on January 23, 2025, Barclays initiated coverage of Exact Sciences (NasdaqCM:EXAS) with a Overweight recommendation.
Analyst Price Forecast Suggests 35.39% Upside
As of December 23, 2024, the average one-year price target for Exact Sciences is $74.66/share. The forecasts range from a low of $60.60 to a high of $99.75. The average price target represents an increase of 35.39% from its latest reported closing price of $55.14 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Exact Sciences is 2,818MM, an increase of 4.67%. The projected annual non-GAAP EPS is -2.35.
What is the Fund Sentiment?
There are 1,157 funds or institutions reporting positions in Exact Sciences. This is an increase of 25 owner(s) or 2.21% in the last quarter. Average portfolio weight of all funds dedicated to EXAS is 0.30%, an increase of 40.81%. Total shares owned by institutions increased in the last three months by 2.96% to 230,714K shares. 
The put/call ratio of EXAS is 0.76, indicating a bullish outlook.
What are Other Shareholders Doing?
Capital World Investors holds 15,841K shares representing 8.56% ownership of the company. In its prior filing, the firm reported owning 16,501K shares , representing a decrease of 4.17%. The firm increased its portfolio allocation in EXAS by 47.16% over the last quarter.
Wellington Management Group Llp holds 14,332K shares representing 7.74% ownership of the company. In its prior filing, the firm reported owning 14,788K shares , representing a decrease of 3.18%. The firm decreased its portfolio allocation in EXAS by 78.50% over the last quarter.
AGTHX - GROWTH FUND OF AMERICA holds 9,651K shares representing 5.21% ownership of the company. In its prior filing, the firm reported owning 8,497K shares , representing an increase of 11.96%. The firm increased its portfolio allocation in EXAS by 6.27% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 5,887K shares representing 3.18% ownership of the company. In its prior filing, the firm reported owning 5,877K shares , representing an increase of 0.16%. The firm increased its portfolio allocation in EXAS by 51.68% over the last quarter.
Jpmorgan Chase holds 5,256K shares representing 2.84% ownership of the company. In its prior filing, the firm reported owning 4,342K shares , representing an increase of 17.40%. The firm increased its portfolio allocation in EXAS by 1,934.42% over the last quarter.
Exact Sciences Background Information
(This description is provided by the company.)
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
